| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34a656200aa70bd912b4ec022c6d37e2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-81 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 |
| filingDate |
1993-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1995-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_220b8999c9e96b26d198f0f981f76f4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9100eaf34e7365d147b50af7ca7969a5 |
| publicationDate |
1995-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5403848-A |
| titleOfInvention |
Diagnosis and treatment of a disorder of the gastrointestinal tract |
| abstract |
Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine) for the treatment of non-ulcerative dyspepsia (NUD), more particularly NUD which is characterized by dysfunction of central 5-HT 1A receptors. Dysfunction of the central 5-HT 1A receptors can be diagnosed by an azaspirodecanedione-induced prolactin response which is distinguishable from that observed in a subject with peptic ulcer disease and/or inflammatory bowel disease. A suitable azaspirodecanedione for inducing the prolactin response is buspirone. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004126318-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5955341-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6596759-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5770356-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8716325-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7098232-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6468738-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2359822-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006258732-A1 |
| priorityDate |
1989-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |